1. |
- Zhang, W., et al.
(author)
-
Decay spectroscopy of 171,172Os and 171,172,174Ir
- 2023
-
In: Physical Review C. - : American Physical Society (APS). - 2469-9985 .- 2469-9993. ; 107:1
-
Journal article (peer-reviewed)abstract
- We report on a study of the α-decay fine structure and the associated Eα−Eγ correlations in the decays of 171,172Os and 171,172,174Ir. In total, 13 new α-decay energy lines have been resolved, and three new γ-ray transitions have been observed following the new decay branches to 168Re and 167W. The weak α-decay branch from the bandhead of the νi13/2 band in 171Os observed in this work highlights an unusual competition between α, β, and electromagnetic decays from this isomeric state. The nucleus 171Os is therefore one of few nuclei observed to exhibit three different decay modes from the same excited state. The nuclei of interest were produced in 92Mo(83Kr,xpyn) fusion-evaporation reactions at the Accelerator Laboratory of the University of Jyväskylä, Finland. The fusion products were selected using the gas-filled ion separator RITU and their decays were characterized using an array of detectors for charged particles and electromagnetic radiation known as GREAT. Prompt γ-ray transitions were detected and correlated with the decays using the JUROGAM II germanium detector array surrounding the target position. Results obtained from total Routhian surface (TRS) calculations suggest that α-decay fine structure and the associated hindrance factors may be a sensitive probe of even relatively small shape changes between the final states in the daughter nucleus.
|
|
2. |
- Chan, Yinghan, et al.
(author)
-
Nutraceuticals : unlocking newer paradigms in the mitigation of inflammatory lung diseases
- 2023
-
In: Critical reviews in food science and nutrition. - : Taylor & Francis. - 1040-8398 .- 1549-7852. ; 63:19, s. 3302-3332
-
Research review (peer-reviewed)abstract
- Persistent respiratory tract inflammation contributes to the pathogenesis of various chronic respiratory diseases, such as asthma, chronic obstructive pulmonary disease, and pulmonary fibrosis. These inflammatory respiratory diseases have been a major public health concern as they are the leading causes of worldwide mortality and morbidity, resulting in heavy burden on socioeconomic growth throughout these years. Although various therapeutic agents are currently available, the clinical applications of these agents are found to be futile due to their adverse effects, and most patients remained poorly controlled with a low quality of life. These drawbacks have necessitated the development of novel, alternative therapeutic agents that can effectively improve therapeutic outcomes. Recently, nutraceuticals such as probiotics, vitamins, and phytochemicals have gained increasing attention due to their nutritional properties and therapeutic potential in modulating the pathological mechanisms underlying inflammatory respiratory diseases, which could ultimately result in improved disease control and overall health outcomes. As such, nutraceuticals have been held in high regard as the possible alternatives to address the limitations of conventional therapeutics, where intensive research are being performed to identify novel nutraceuticals that can positively impact various inflammatory respiratory diseases. This review provides an insight into the utilization of nutraceuticals with respect to their molecular mechanisms targeting multiple signaling pathways involved in the pathogenesis of inflammatory respiratory diseases.
|
|
3. |
- Patel, Vyoma K., et al.
(author)
-
Tackling the cytokine storm using advanced drug delivery in allergic airway disease
- 2023
-
In: Journal of Drug Delivery Science and Technology. - : Elsevier. - 1773-2247. ; 82
-
Research review (peer-reviewed)abstract
- Asthma is one of the leading causes of mortality worldwide presenting a huge socio-economic burden with rising morbidity and mortality rates. It is a chronic inflammatory airway disease that is eminent with multiple epidemiological and pathophysiological features such as over production of pro-inflammatory cytokines that triggers an uncontrolled aberrant inflammatory response known as 'cytokine storm'. This phenomenon interferes with the signalling and production of cytokines over time leading to the progression of disease and the development of complications that lead to fatal consequences in many individuals. Targeting this overproduction and signalling of cytokines may prove a promising approach to develop novel cytokine specific therapies in the treatment of asthma. This review discusses on the various pharmacological strategies, recent advancements in drug delivery systems and significant findings from clinical trials that may have a potential to outweigh the limitations of the current therapies in the treatment of asthma.
|
|